IP Library › Granted Patent US 8,557,782
Granted Patent B2
US 8,557,782 · App. 12/796,866 · Granted Oct 15, 2013

Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture

Inventors: Matthias Eckhardt (Biberach, DE); Frank Himmelsbach (Mittelbiberach, DE); Peter Eickelmann (Mittelbiberach, DE); Achim Sauer (Ravensburg-Torkenweiler, DE); Leo Thomas (Biberach, DE)
Assignee: Boehringer Ingelheim International GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,557,782
App. No.
12/796,866
Granted
Oct 15, 2013
Kind
B2
Abstract

Glucopyranosyl-substituted benzonitrile derivatives defined according to claim 1 , including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.

Claims (26)

1. A glucopyranosyl-substituted benzonitrile derivative selected from the group consisting of:

2-(4-Ethyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile;

4-(β-D-glucopyranos-1-yl)-2-(4-methyl-benzyl)-benzonitrile;

4-(β-D-glucopyranos-1-yl)-2-(4-isopropyl-benzyl)-benzonitrile;

2-(4-Difluoromethoxy-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile;

2-(4-Difluoromethyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile;

2-(4-Cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile;

2-(4-Cyclobutyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile; and

4-(β-D-glucopyranos-1-yl)-2-(4-prop-1-yl-benzyl)-benzonitrile.

2. A pharmaceutical composition comprising a compound according to claim 1 .

3. 2-(4-Ethyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile.

4. A pharmaceutical composition comprising the compound according to claim 3 .

5. 4-(β-D-glucopyranos-1-yl)-2-(4-methyl-benzyl)-benzonitrile.

6. A pharmaceutical composition comprising the compound according to claim 5 .

7. 4-(β-D-glucopyranos-1-yl)-2-(4-isopropyl-benzyl)-benzonitrile.

8. A pharmaceutical composition comprising the compound according to claim 7 .

9. 2-(4-Difluoromethoxy-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile.

10. A pharmaceutical composition comprising the compound according to claim 9 .

11. 2-(4-Difluoromethyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile.

12. A pharmaceutical composition comprising the compound according to claim 11 .

13. 2-(4-Cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile.

14. A pharmaceutical composition comprising the compound according to claim 13 .

15. 2-(4-Cyclobutyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzonitrile.

16. A pharmaceutical composition comprising the compound according to claim 15 .

17. 4-(β-D-glucopyranos-1-yl)-2-(4-prop-1-yl-benzyl)-benzonitrile.

18. A pharmaceutical composition comprising the compound according to claim 17 .

Priority Claims (3)
EP 06113412 · May 3, 2006 · regional
EP 06124833 · Nov 27, 2006 · regional
WO PCT/EP2007/051411 · Feb 14, 2007 · international
Continuity (2)
Continuation 11742612 · May 1, 2007
Related Publication 20100249392A1 · Sep 30, 2010